RTW Biotech Opportunities (LSE:RTW) ROCE %: % (As of Dec. 2025)


LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
36 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities ROCE %?

RTW Biotech Opportunities LSE:RTW +2.68% 36 ROCE % is % as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

ROCE % does not apply to banks and insurance companies.

LSE:RTW
36GF Score
RTW Biotech Opportunities Ltd LSE:RTW
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of % mean?
RTW Biotech Opportunities (LSE:RTW) has a ROCE % of % as of Dec. 2025.
Is RTW Biotech Opportunities' ROCE % too high?
RTW Biotech Opportunities' current ROCE % is %. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' ROCE % compare to BLK and BX?
RTW Biotech Opportunities' ROCE % of % can be compared against companies in the Asset Management industry. The industry median ROCE % is 4.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for an Asset Management company?
The median ROCE % among Asset Management companies is 4.43, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Asset Management industry, the median ROCE % is 4.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current ROCE % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current ROCE % of %. The current ROCE % is %. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current ROCE % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score

Get the complete analysis for LSE:RTW

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price